Terms: = Breast cancer AND STAT5B, STAT5, 6777, ENSG00000173757, P51692 AND Prognosis
33 results:
1. Identification of stat5b as a biomarker associated with prognosis and immune infiltration in breast cancer.
Li J; Li L; Mahesutihan G; Meng J; Chen Y; Lv J
Medicine (Baltimore); 2023 Mar; 102(9):e32972. PubMed ID: 36862902
[TBL] [Abstract] [Full Text] [Related]
2. stat5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential.
Lin M; Ku AT; Dong J; Yue F; Jiang W; Ibrahim AA; Peng F; Creighton CJ; Nagi C; Gutierrez C; Rosen JM; Zhang XH; Hilsenbeck SG; Chen X; Du YN; Huang S; Shi A; Fan Z; Li Y
Oncogene; 2022 Nov; 41(48):5214-5222. PubMed ID: 36261627
[TBL] [Abstract] [Full Text] [Related]
3. Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma.
Liang HC; Costanza M; Prutsch N; Zimmerman MW; Gurnhofer E; Montes-Mojarro IA; Abraham BJ; Prokoph N; Stoiber S; Tangermann S; Lobello C; Oppelt J; Anagnostopoulos I; Hielscher T; Pervez S; Klapper W; Zammarchi F; Silva DA; Garcia KC; Baker D; Janz M; Schleussner N; Fend F; Pospíšilová Š; Janiková A; Wallwitz J; Stoiber D; Simonitsch-Klupp I; Cerroni L; Pileri S; de Leval L; Sibon D; Fataccioli V; Gaulard P; Assaf C; Knörr F; Damm-Welk C; Woessmann W; Turner SD; Look AT; Mathas S; Kenner L; Merkel O
Nat Commun; 2021 Sep; 12(1):5577. PubMed ID: 34552066
[TBL] [Abstract] [Full Text] [Related]
4. The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts.
Zhong Y; Deng L; Shi S; Huang QY; Ou-Yang SM; Mo JS; Zhu K; Qu XM; Liu PQ; Wang YX; Zhang XL
Acta Pharmacol Sin; 2022 Apr; 43(4):1013-1023. PubMed ID: 34267347
[TBL] [Abstract] [Full Text] [Related]
5. CircNOL10 suppresses breast cancer progression by sponging miR-767-5p to regulate SOCS2/JAK/STAT signaling.
Wang F; Wang X; Li J; Lv P; Han M; Li L; Chen Z; Dong L; Wang N; Gu Y
J Biomed Sci; 2021 Jan; 28(1):4. PubMed ID: 33397365
[TBL] [Abstract] [Full Text] [Related]
6. Contribution of Immune Cells to Glucocorticoid Receptor Expression in breast cancer.
Gandhi S; Elkhanany A; Oshi M; Dai T; Opyrchal M; Mohammadpour H; Repasky EA; Takabe K
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629782
[TBL] [Abstract] [Full Text] [Related]
7. Fibroblasts as a Biological Marker for Curative Resection in Pancreatic Ductal Adenocarcinoma.
Katsuta E; Rashid OM; Takabe K
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32485981
[TBL] [Abstract] [Full Text] [Related]
8. Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer.
Gasparyan M; Lo MC; Jiang H; Lin CC; Sun D
J Biol Chem; 2020 Aug; 295(34):12188-12202. PubMed ID: 32467227
[TBL] [Abstract] [Full Text] [Related]
9. Identification of an AP1-ZFP36 Regulatory Network Associated with breast cancer prognosis.
Canzoneri R; Naipauer J; Stedile M; Rodriguez Peña A; Lacunza E; Gandini NA; Curino AC; Facchinetti MM; Coso OA; Kordon E; Abba MC
J Mammary Gland Biol Neoplasia; 2020 Jun; 25(2):163-172. PubMed ID: 32248342
[TBL] [Abstract] [Full Text] [Related]
10. Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary breast cancer Predicts Poor Clinical Outcome and Correlates with Suppressed stat5 Signaling.
Tran TH; Utama FE; Sato T; Peck AR; Langenheim JF; Udhane SS; Sun Y; Liu C; Girondo MA; Kovatich AJ; Hooke JA; Shriver CD; Hu H; Palazzo JP; Bibbo M; Auer PW; Flister MJ; Hyslop T; Mitchell EP; Chervoneva I; Rui H
Clin Cancer Res; 2018 Dec; 24(24):6355-6366. PubMed ID: 30097435
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic roles of signal transducers and activators of transcription family in human breast cancer.
Wang S; Yu L; Shi W; Li X; Yu L
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 29326301
[TBL] [Abstract] [Full Text] [Related]
12. Interleukin 7 receptor alpha Thr244Ile genetic polymorphism is associated with susceptibility and prognostic markers in breast cancer subgroups.
Vitiello GAF; Losi Guembarovski R; Amarante MK; Ceribelli JR; Carmelo ECB; Watanabe MAE
Cytokine; 2018 Mar; 103():121-126. PubMed ID: 28964592
[TBL] [Abstract] [Full Text] [Related]
13. Nuclear staining of fgfr-2/stat-5 and runx-2 in mucinous breast cancer.
May M; Mosto J; Vazquez PM; Gonzalez P; Rojas P; Gass H; Lanari C; Molinolo AA
Exp Mol Pathol; 2016 Feb; 100(1):39-44. PubMed ID: 26551078
[TBL] [Abstract] [Full Text] [Related]
14. STAT3 genetic variant, alone and in combination with stat5b polymorphism, contributes to breast cancer risk and clinical outcomes.
Zhao H; Wang Z; Wu H; Xiao Q; Yao W; Wang E; Liu Y; Wei M
Med Oncol; 2015 Jan; 32(1):375. PubMed ID: 25487443
[TBL] [Abstract] [Full Text] [Related]
15. IL15RA drives antagonistic mechanisms of cancer development and immune control in lymphocyte-enriched triple-negative breast cancers.
Marra P; Mathew S; Grigoriadis A; Wu Y; Kyle-Cezar F; Watkins J; Rashid M; De Rinaldis E; Hessey S; Gazinska P; Hayday A; Tutt A
Cancer Res; 2014 Sep; 74(17):4908-21. PubMed ID: 24980552
[TBL] [Abstract] [Full Text] [Related]
16. stat5 in breast cancer: potential oncogenic activity coincides with positive prognosis for the disease.
Barash I
Carcinogenesis; 2012 Dec; 33(12):2320-5. PubMed ID: 23161573
[TBL] [Abstract] [Full Text] [Related]
17. Low levels of stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes.
Peck AR; Witkiewicz AK; Liu C; Klimowicz AC; Stringer GA; Pequignot E; Freydin B; Yang N; Ertel A; Tran TH; Girondo MA; Rosenberg AL; Hooke JA; Kovatich AJ; Shriver CD; Rimm DL; Magliocco AM; Hyslop T; Rui H
Breast Cancer Res; 2012 Oct; 14(5):R130. PubMed ID: 23036105
[TBL] [Abstract] [Full Text] [Related]
18. Hypoxia upregulates Hsp90α expression via stat5b in cancer cells.
Pak SH; Joung YH; Park JH; Lim EJ; Darvin P; Na YM; Hong DY; Lee B; Hwang TS; Park T; Ye SK; Moon ES; Cho BW; Park KD; Lee HK; Chung IM; Yang YM
Int J Oncol; 2012 Jul; 41(1):161-8. PubMed ID: 22552610
[TBL] [Abstract] [Full Text] [Related]
19. The biology of progesterone receptor in the normal mammary gland and in breast cancer.
Obr AE; Edwards DP
Mol Cell Endocrinol; 2012 Jun; 357(1-2):4-17. PubMed ID: 22193050
[TBL] [Abstract] [Full Text] [Related]
20. Loss of nuclear localized and tyrosine phosphorylated stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure.
Peck AR; Witkiewicz AK; Liu C; Stringer GA; Klimowicz AC; Pequignot E; Freydin B; Tran TH; Yang N; Rosenberg AL; Hooke JA; Kovatich AJ; Nevalainen MT; Shriver CD; Hyslop T; Sauter G; Rimm DL; Magliocco AM; Rui H
J Clin Oncol; 2011 Jun; 29(18):2448-58. PubMed ID: 21576635
[TBL] [Abstract] [Full Text] [Related]
[Next]
